MedTrace Logo

Demodex Blepharitis in Scleral Lens Wearers

NCT07561450 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-05-01

No results posted yet for this study

Summary

The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance.

The investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.

Conditions

  • Demodex Blepharitis

Interventions

DRUG

Xdemvy

All subjects enrolled inthis study will be treated with xdemvy

Sponsors & Collaborators

  • Boston Sight

    lead OTHER

Principal Investigators

  • Daniel Brocks, MD · Boston Sight

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2026-08-31
Completion
2027-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07561450 on ClinicalTrials.gov